Current Report Filing (8-k)

0001745020false00017450202022-01-102022-01-10

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date Earliest Event Reported):

January 10, 2022

Theseus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

​	​	​	​	​
Delaware		001-40869		83-0712806
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​ ​ ​	​	​ ​
245 Main Street Cambridge, Massachusetts (Address of Principal Executive Offices)		02142 (Zip Code)

​

[phone]

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​ ​	​	​ ​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		THRX		The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

​

​

​

Item 8.01

Other Events.

​

On January 10, 2022, Theseus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the first patient has been treated in the Phase 1 portion of the Company’s ongoing Phase 1/2 study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors, as well as indicating its expectations with respect to the presentation of initial data from the Phase 1 portion of the clinical trial. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

​

Item 9.01

Financial Statements and Exhibits.

​

(d) Exhibits

No.		Description of Exhibit
99.1	​	Press release issued by Theseus Pharmaceuticals, Inc. on January 10, 2022
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​	​
​	Theseus Pharmaceuticals, Inc.
​	​
​	By:	/s/ Bradford D. Dahms
​	​	Name: Bradford D. Dahms
​	​	Title: Chief Financial Officer

​

Date: January 10, 2022

​

​